



Le Locle and Lausanne (Switzerland), Besançon (France)

June 20, 2019

DIXI Group partners with Aleva Neurotherapeutics to develop new generation of deep brain surgical electrodes for epilepsy treatment

DIXI Holding Le Locle SA and Aleva Neurotherapeutics SA have co-founded Adept Neuro SA, a Joint Venture dedicated to developing a new generation of Stereo-Electro-Encephalo-Graphie (SEEG) electrodes which will facilitate localization and thermocoagulation of epileptogenic zones.

Aleva Neurotherapeutics, a spin-off of the Swiss Federal Institute of Technology (EPFL) Microsystems Laboratory, has developed a unique technology for the manufacture of electrodes allowing precise stimulation of the deep brain. Aleva's electrodes are based on MEMS technology, which allows great flexibility of design and miniaturization, opening the door to new product development avenues and cost efficient industrialization of the manufacturing process.

DIXI Medical SAS in Besançon is the world leader in the manufacture of intracerebral electrodes for SEEG. The current conventional mode of production limits the company's ability to meet the demand of a rapidly growing market and prohibits the necessary evolution in therapeutic modalities that only the nanotech dimension can facilitate.

Adept Neuro has exclusive intellectual property rights developed by Aleva Neurotherapeutics in the field of epilepsy. DIXI Holding will ensure the full financing of the joint venture and will gradually become the sole shareholder, while DIXI Medical SAS will ensure the exclusive production and distribution of products developed by Adept Neuro.

Dr André Mercanzini, CEO of Aleva Neurotherapeutics SA (Lausanne, Switzerland) explains the importance of the partnership: "Our technology has demonstrated its clinical efficacy in the most demanding applications of neurosurgery. With the long and pioneering experience of Dixi in Epilepsy, we are sure to transform the lives of patients for the better"

Mr Frédéric Koehn COO of DIXI Holding SA (Le Locle, Switzerland) stressed that this investment is a major sign of the Dixi Group's new ambitions: "Dixi is dedicated to improving the lives of epileptic patients by providing new technologies to Neurologists and Neurosurgeons. We aim to become a major integrated player for the diagnostic and surgical treatment of Epilepsy."

Adept Neuro SA will be based at the EPFL Innovation Park in Lausanne, Switzerland.

-Ends-

About Aleva Neurotherapeutics www.aleva-neuro.com

Aleva Neurotherapeutics develops next-generation neurostimulation technologies and devices for Deep Brain Stimulation (DBS) therapy. Its solutions are designed to be more precise and more efficient than currently available DBS approaches while causing fewer side effects. Based on its proprietary technology, Aleva has developed novel brain stimulating products with different properties. The first, called directSTIM™, is a complete Directional Deep Brain Stimulation System for long-term therapy in Parkinson's Disease and Essential Tremor.

The company is a spin-off from the Ecole Polytechnique Fédérale de Lausanne (EPFL) Microsystems Laboratory of Prof. Philippe Renaud. Aleva Neurotherapeutics has raised over USD 40 million from renowned private and institutional investors.

About Dixi Group www.dixi.ch

Dixi is a family owned industrial conglomerate active in industrial tooling, microtechnology, medical devices and micromechanics subcontracting. Its 600+ collaborators are located mainly between Switzerland and France with subsidiaries in the USA, the Netherland, Spain and Germany.

Media Inquiries:

Richard Kenyon

+44 7831 569940

richardkenyon44@hotmail.com